Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment-Reference-Cited by-同舟云学术

Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment

Published:2021-07 Issue:1 Volume:148 Page:266-271.e2
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Busse William W.,Bleecker Eugene R.,FitzGerald J. Mark,Ferguson Gary T.,Barker Peter,Brooks Laura,Olsson Richard F.,Martin Ubaldo J.,Goldman Mitchell

Funder

AstraZeneca PLC

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference10 articles.

1. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur Respir J,2014

2. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice;Price;J Asthma Allergy,2016

3. Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study;Talini;BMJ Open,2015

4. Benralizumab: a unique IL-5 inhibitor for severe asthma;Tan;J Asthma Allergy,2016

5. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function;Kolbeck;J Allergy Clin Immunol,2010

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The perceived waning of biologics in severe asthma;Respiratory Medicine;2023-11

2. Severe Asthma and Biological Therapies: Now and the Future;Journal of Clinical Medicine;2023-09-08

3. New approaches in childhood asthma treatment;Current Opinion in Allergy & Clinical Immunology;2023-06-23

4. The clinical efficacy of type 2 monoclonal antibodies in eosinophil-associated chronic airway diseases: a meta-analysis;Frontiers in Immunology;2023-04-11

5. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy;Allergology International;2023-01